Medexus Pharmaceuticals Inc. - Laporan Laba Rugi (TTM)

Medexus Pharmaceuticals Inc.
CA ˙ TSX ˙ CA58410Q2036
CA$ 3.08 ↑0.03 (0.98%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Medexus Pharmaceuticals Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 69 79 80 77 77 74 77 82 92 100 108 117 119 116 113 109 105 110 108 106
Change (%) 15.14 0.47 -3.43 0.17 -3.87 3.54 7.53 11.86 8.09 8.39 7.87 2.26 -2.95 -2.31 -3.78 -3.70 4.56 -1.10 -2.46
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 27 32 32 33 34 32 33 33 36 39 42 47 49 49 48 46 44 46 45 42
Change (%) 18.70 -0.42 3.48 0.89 -5.54 4.05 -0.72 9.31 8.40 8.95 10.09 5.48 -0.49 -1.90 -3.82 -4.33 4.47 -2.83 -5.83
% of Revenue 39.54 40.76 40.40 43.29 43.60 42.85 43.06 39.76 38.85 38.96 39.16 39.97 41.22 42.27 42.44 42.43 42.15 42.11 41.38 39.95
Gross Operating Profit 42 47 47 44 43 42 44 50 56 61 66 70 70 67 65 63 61 63 64 63
Change (%) 12.81 1.09 -8.11 -0.38 -2.59 3.16 13.77 13.55 7.89 8.04 6.44 0.12 -4.68 -2.61 -3.75 -3.23 4.63 0.15 -0.09
% of Revenue 60.46 59.24 59.60 56.71 56.40 57.15 56.94 60.24 61.15 61.04 60.84 60.03 58.78 57.73 57.56 57.57 57.85 57.89 58.62 60.05
SG&A 31 33 36 40 43 44 44 44 46 47 48 48 47 46 45 43 41 41 43 45
Change (%) 4.17 10.65 9.56 8.74 3.02 -0.81 0.91 2.53 2.63 3.20 -0.47 -1.98 -2.52 -2.23 -3.45 -5.13 0.68 4.37 4.21
% of Revenue 45.57 41.23 45.41 51.51 55.92 59.93 57.41 53.87 49.38 46.88 44.64 41.19 39.48 39.66 39.69 39.82 39.23 37.77 39.86 42.59
R&D 2 3 5 6 7 7 6 4 3 3 3 3 3 2 2 1 1 1 1 2
Change (%) 36.65 56.88 34.51 16.06 -1.67 -16.75 -26.73 -21.31 -10.10 -3.32 -7.48 -4.22 -12.31 -29.73 -21.41 -36.42 0.87 51.60 48.13
% of Revenue 3.11 3.70 5.77 8.04 9.31 9.52 7.66 5.22 3.67 3.05 2.72 2.34 2.19 1.98 1.42 1.16 0.77 0.74 1.13 1.72
OpEx 66 73 79 85 90 89 89 88 91 95 100 103 105 103 100 97 92 95 96 97
Change (%) 11.49 7.53 7.95 5.66 -0.76 -0.29 -1.62 3.71 4.27 5.11 3.74 1.37 -1.73 -2.59 -3.75 -4.73 2.79 2.02 0.84
% of Revenue 95.61 92.58 99.08 110.76 116.82 120.60 116.14 106.25 98.50 95.03 92.15 88.62 87.85 88.95 88.69 88.71 87.76 86.27 89.00 92.01
Operating Income 3 6 1 -8 -13 -15 -12 -5 1 5 8 13 14 13 13 12 13 15 12 8
Change (%) 94.74 -87.58 -1,232.01 56.66 17.73 -18.91 -58.36 -126.84 258.71 71.11 56.30 9.23 -11.76 -0.02 -3.99 4.45 17.26 -20.72 -29.19
% of Revenue 4.39 7.42 0.92 -10.76 -16.82 -20.60 -16.14 -6.25 1.50 4.97 7.85 11.38 12.15 11.05 11.31 11.29 12.24 13.73 11.00 7.99
Interest Expense -8 -9 -10 -10 -11 -12 -12 -12 -13 -13 -14 -15 -16 -15 -13 -11 -9 -8 -8 -8
Change (%) 6.39 8.83 5.65 6.09 6.00 4.80 2.17 1.77 3.08 3.85 8.13 6.36 -5.73 -9.41 -16.64 -18.55 -7.27 -2.60 -7.63
% of Revenue -12.31 -11.38 -12.32 -13.48 -14.28 -15.74 -15.94 -15.14 -13.77 -13.14 -12.59 -12.62 -13.12 -12.75 -11.82 -10.24 -8.66 -7.68 -7.56 -7.16
Net Income -9 -19 -28 -31 -20 -8 -3 2 -11 -11 1 3 5 6 -0 1 2 4 2 1
Change (%) 124.48 46.94 11.17 -37.26 -59.01 -64.38 -180.24 -557.36 3.38 -111.18 167.81 50.06 19.83 -103.64 -610.28 110.16 55.21 -36.92 -64.13
% of Revenue -12.44 -24.26 -35.48 -40.84 -25.58 -10.91 -3.75 2.80 -11.45 -10.95 1.13 2.80 4.12 5.08 -0.19 1.00 2.19 3.25 2.07 0.76

Source: Capital IQ

Other Listings
DE:P731 € 1.83
US:MEDXF
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista